Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.59 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8951934 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17748427 | 0.99 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5567911 | 0.93 | P2RY2 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL11992613 | 0.92 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17014892 | 0.92 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6879979 | 0.92 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3868100 | 0.89 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7456562 | 0.88 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6673272 | 0.88 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL4064962 | 0.88 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011133580-A1 | USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS | BACK BAY SCIENTIFIC LLC (US) | 2011-10-27 | — | — | WO | claimed |
| US-20110257109-A1 | USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS | BACK BAY SCIENTIFIC, LLC | 2011-10-20 | — | — | US | claimed |
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| CN-114903903-A | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-109310695-B | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5583117-A | CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; DIABETES | PRO-NEURON, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | SLC28A1 345/4885SLC28A2 315/4885SLC29A1 273/4885 |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | SLC28A1 1459/4885SLC28A2 1402/4885SLC29A1 2267/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | SLC28A1 1459/4885SLC28A2 1402/4885SLC29A1 2267/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC28A1 1459/4885SLC28A2 1402/4885SLC29A1 2267/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC28A1 1459/4885SLC28A2 1402/4885SLC29A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.